Suzanne Aldington is a Director in the Cell and Gene Therapy Technology group at Orchard Therapeutics in London, where she has worked since the beginning of 2020. Previously she was at Lonza, a Contract Manufacturer based in Slough, UK for 20 years. During this time her experience included purification process development, scale up activities at non GMP pilot scale and subsequent process transfers into GMP manufacturing facilities. In addition, she gained considerable experience in process validation including supporting multiple on site inspections by the FDA and other Health Agencies. She has over 30 years experience in academia and in the biotechnology industry. After completing a degree in Microbiology at Imperial College, she studied for a PhD in biochemical engineering at Birmingham University which included purification of an enzyme produced in microbial culture.
